Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether dual antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to lower fatal or nonfatal myocardial infarction compared with control (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
1 finding from 1 review
Death (any cause) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
1 finding from 1 review
Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
1 finding from 1 review
Minor bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).
1 finding from 1 review
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review
Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes any bleeding that does not meet criteria for major bleeding ‐… compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
1 finding from 1 review
Outcomes (measurement) · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological impairment · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ipsilateral major or disabling stroke · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in ipsilateral major or disabling stroke (CT scan or MRI) compared with placebo (low certainty).
1 finding from 1 review
Stroke‐related mortality · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in stroke‐related mortality (CT scan or MRI) compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · asymptomatic carotid stenosis
It is very uncertain whether antiplatelet agent changes major bleeding (not reported) compared with placebo (very low certainty).
1 finding from 1 review
Progression of carotid stenosis · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in progression of carotid stenosis (DUS/every 6 months) compared with placebo (low certainty).
1 finding from 1 review
Adverse events (not reported) · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in adverse events (not reported) compared with placebo (low certainty).
1 finding from 1 review
Quality of life · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found